Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.
- DOI
- 10.1177/17562864261444676
- Published
- 2026
- Container
- Therapeutic advances in neurological disorders
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17562864261444676,
title = {Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.},
author = {de Keijzer C and E JY and Yang Q and Gitonga R and Hiller D and Jurgensen S and Salloum N and Cunha-Santos J and Hoogewys-Cynober E and Vinet L and Chirieac M and Benzerdjeb H and Thoene D and Ziemssen T and Drahota J and Horáková D and Brown W and Hobart J and Robertson NP and Hakkarainen KM and Sinnott SJ},
year = {2026},
journal = {Therapeutic advances in neurological disorders},
doi = {10.1177/17562864261444676},
url = {https://doi.org/10.1177/17562864261444676}
}RIS
TY - JOUR TI - Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries. AU - de Keijzer C AU - E JY AU - Yang Q AU - Gitonga R AU - Hiller D AU - Jurgensen S AU - Salloum N AU - Cunha-Santos J AU - Hoogewys-Cynober E AU - Vinet L AU - Chirieac M AU - Benzerdjeb H AU - Thoene D AU - Ziemssen T AU - Drahota J AU - Horáková D AU - Brown W AU - Hobart J AU - Robertson NP AU - Hakkarainen KM AU - Sinnott SJ PY - 2026 JO - Therapeutic advances in neurological disorders DO - 10.1177/17562864261444676 UR - https://doi.org/10.1177/17562864261444676 ER -
APA
C, D. K., JY, E., Q, Y., R, G., D, H., S, J., N, S., J, C., E, H., L, V., M, C., H, B., D, T., T, Z., J, D., D, H., W, B., J, H., NP, R., KM, H., & SJ, S. (2026). Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries.. Therapeutic advances in neurological disorders. https://doi.org/10.1177/17562864261444676
Source records
- pubmed · retrieved 2026-09-25T10:30:45.078Z
- europe-pmc · retrieved 2026-09-25T10:30:45.091Z
- doaj · retrieved 2026-09-25T10:30:45.077Z